TY - JOUR
T1 - X-ray structures and mechanism of the human serotonin transporter
AU - Coleman, Jonathan A.
AU - Green, Evan M.
AU - Gouaux, Eric
N1 - Funding Information:
We thank D. Cawley for generating monoclonal antibodies and Lundbeck for Br-citalopram. We thank A. Penmatsa and K. Wang for assistance with initial crystal screening, K. Dürr and W. Lü for help with Fab crystallization and structure refinement, respectively, L. Vaskalis for assistance with figures, H. Owen for help with manuscript preparation and other Gouaux laboratory members for discussions. We acknowledge the staff of the Berkeley Center for Structural Biology at the Advanced Light Source and the Northeastern Collaborative Access Team at the Advanced Photon Source for assistance with data collection. J.A.C. has support from a Banting postdoctoral fellowship from the Canadian Institutes of Health Research. We are particularly grateful to Bernie and Jennifer LaCroute for their generous support, as well as for funding from the National Institutes of Health (NIH) (5R37MH070039). E.G. is an Investigator with the Howard Hughes Medical Institute.
Publisher Copyright:
© 2016 Macmillan Publishers Limited. All rights reserved.
PY - 2016/4/21
Y1 - 2016/4/21
N2 - The serotonin transporter (SERT) terminates serotonergic signalling through the sodium- and chloride-dependent reuptake of neurotransmitter into presynaptic neurons. SERT is a target for antidepressant and psychostimulant drugs, which block reuptake and prolong neurotransmitter signalling. Here we report X-ray crystallographic structures of human SERT at 3.15 Å resolution bound to the antidepressants (S)-citalopram or paroxetine. Antidepressants lock SERT in an outward-open conformation by lodging in the central binding site, located between transmembrane helices 1, 3, 6, 8 and 10, directly blocking serotonin binding. We further identify the location of an allosteric site in the complex as residing at the periphery of the extracellular vestibule, interposed between extracellular loops 4 and 6 and transmembrane helices 1, 6, 10 and 11. Occupancy of the allosteric site sterically hinders ligand unbinding from the central site, providing an explanation for the action of (S)-citalopram as an allosteric ligand. These structures define the mechanism of antidepressant action in SERT, and provide blueprints for future drug design.
AB - The serotonin transporter (SERT) terminates serotonergic signalling through the sodium- and chloride-dependent reuptake of neurotransmitter into presynaptic neurons. SERT is a target for antidepressant and psychostimulant drugs, which block reuptake and prolong neurotransmitter signalling. Here we report X-ray crystallographic structures of human SERT at 3.15 Å resolution bound to the antidepressants (S)-citalopram or paroxetine. Antidepressants lock SERT in an outward-open conformation by lodging in the central binding site, located between transmembrane helices 1, 3, 6, 8 and 10, directly blocking serotonin binding. We further identify the location of an allosteric site in the complex as residing at the periphery of the extracellular vestibule, interposed between extracellular loops 4 and 6 and transmembrane helices 1, 6, 10 and 11. Occupancy of the allosteric site sterically hinders ligand unbinding from the central site, providing an explanation for the action of (S)-citalopram as an allosteric ligand. These structures define the mechanism of antidepressant action in SERT, and provide blueprints for future drug design.
UR - http://www.scopus.com/inward/record.url?scp=84964498770&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964498770&partnerID=8YFLogxK
U2 - 10.1038/nature17629
DO - 10.1038/nature17629
M3 - Article
C2 - 27049939
AN - SCOPUS:84964498770
SN - 0028-0836
VL - 532
SP - 334
EP - 339
JO - Nature
JF - Nature
IS - 7599
ER -